Insights on cholesterol nutrition: shift to a new paradigm for better cardiovascular health

[1] I. Björkheim, H. Danielsson, K. Einarsson, G. Johansson, “Formation of bile acids in man: conversion of cholesterol into 5-
beta-cholestane-3-alpha, 7-alpha, 12-alpha-triol in liver homogenates,” J Clin Invest, vol. 7, pp. 1573-82, 1968.
[2] B. A. Golomb, “Cholesterol and violence: is there a connection?,” Ann Intern Med, vol. 6, pp. 478-87, 1998.
[3] M. Virkkunen, “Serum cholesterol in antisocial personality,” Neuropsychobiology, Vol. 1, pp. 27-30, 1979.
[4] A. Valevski, I. Modai, and S. Dror, “Serum cholesterol levels and suicidal tendencies in psychiatric inpatients,” J Clin
Psychiatry, vol. 6, pp. 252-4, 1994.
[5] A. Tanskanen, J. Tuomilehto, and H. Viinamäki, “Cholesterol, depression and suicide,” The British Journal of Psychiatry,
vol. 176, pp. 398-399, 2000.
[6] M. Zureik, D. Courbon, and P. Ducimetiere, “Serum cholesterol concentration and death from suicide in men,” Paris
prospective study, I. BMJ, vol. 313, pp. 649-51, 1996.
[7] T. Partonen, J. Haukka, and J. Virtamo, “Association of low serum total cholesterol with major depression and suicide,”
British Journal of Psychiatry, vol. 175, pp. 259 -262, 1999.
[8] A. Lalovic, and G.Turecki, “Cholesterol metabolism and suicidality,” Directions in Psychiatry, vol. 26, pp. 209-17, 2006.
[9] A. Lalovic, É. Levy, and L. Canetti, “Fatty acid composition in postmortem brains of people who completed suicide,” J
Psychiatry Neurosci, Vol. 5, pp. 363–370, 2007.
[10] H. Engelberg, “Low serum cholesterol and suicide,” Lancet, vol. 339, pp. 727-9, 1992.
[11] M. Huan, K. Hamazaki, and Y. Sun, “Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in
China,” Biol Psychiatry, vol. 7, pp. 490-6, 2004.
[12] J. Shepherd, S. Cobbe and I. Ford, “West of Scotland Coronary Prevention Study Group, Prevention of coronary heart
disease with pravastatin in men with hypercholesterolemia,” N Engl J Med, pp. 3331301- 1307, 1995.
[13] The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group, “Prevention of cardiovascular
events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol
levels,” N Engl J Med, vol. 339, no. 19, pp. 1349- 1357, 1998.
DOI: 10.1056/NEJM199811053391902
[14] JR Downs, M Clearfield, S Weis, E Whitney, DR Shapiro, PA Beere, A Langendorfer, EA Stein, W Kruyer, AM Jr. Gotto,
“Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels:
results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study,” JAMA, vol. 279, no. 20, pp.
1615- 1622, 1998.
[15] Scandinavian Simvastatin Survival Study Group, “Randomised trial of cholesterol lowering in 4444 patients with
coronary artery disease: The Scandinavian Simvastatin Survival Study (4S),” Lancet, vol. 344, no. 8934, pp. 1383-1389,
1994.
Ghose Bishwajit, Marce - Amara Kpoghomou, Hasanbek Shamsitdinov, Arun Kumar Mondal, and Sudeb Sarker
ISSN : 2028-9324 Vol. 4 No. 3, Nov. 2013 521
[16] F.M. Sacks, M.A. Pfeffer, and L.A. Moye, “The effect of pravastatin on coronary events after myocardial infarction in
patients with average cholesterol levels,” N Engl J Med, vol. 335, pp. 1001-1009, 1996.
[17] MB Fontenot, JR Kaplan, CA Shively, SB Manuck, JJ Mann, “Cholesterol, serotonin, and behavior in young monkeys,” Ann
N Y Acad Sci., vol. 794, pp. 352-354, 1996.
[18] J.R. Kaplan, C.A. Shively, and M.B. Fontenot, “Demonstration of an association among dietary cholesterol, central
serotonergic activity, and social behavior in monkeys,” Psychosom Med, vol. 56, pp. 479- 484, 1994.
[19] J. Brunner, K.G. Parhofer, and P. Schwandt, “Cholesterol, essential fatty acids, and suicide,” Pharmacopsychiatry, vol. 1,
pp. 1-5, 2002.
[20] J.M. Dietschy and S.D. Turley, “Cholesterol metabolism in the brain,” Curr Opin Lipidol, vol. 2, pp. 105-121, 2001.
[21] Mary G. Enig, Know Your Fats: The Complete Primer for Understanding the Nutrition of Fats, Oils and Cholesterol,
Bethesda Press, 2000.
ISBN-10: 0967812607
[22] S.M. Scanlon, D.C. Williams, and P. Schloss, “Membrane cholesterol modulates serotonin transporter activity,”
Biochemistry, vol. 40, no. 35, pp. 10507-13, 2001.
[23] National Heart, Lung, and Blood Institute, Third Report of the Expert Panel on Detection, Evaluation, and Treatment of
High Blood Cholesterol in Adults (Adult Treatment Panel III), National Cholesterol Education Program (NCEP), NIH
Publication No. 02-5215, September 2002.
[24] David E. Golan, Armen H. Tashjian, Ehrin J. Armstrong, April W. Armstrong, Principles of Pharmacology: The
Pathophysiologic Basis of Drug Therapy, Lippincott Williams & Wilkins; Third, North American Edition edition, 2011.
[25] C. Stancu, and A. Sima, “Statins: mechanism of action and effects,” J Cell Mol Med, vol. 4, pp. 378-87, 2001.
[26] F. Lakha, E. Theodoratou, and SM. Farrington, “Statin use and association with colorectal cancer survival and risk: case
control study with prescription data linkage,” 12:487, 2012.
DOI: 10.1186/1471-2407-12-487
[27] C. Hachem, R. Morgan, and M. Johnson, “Statins and the risk of colorectal carcinoma: a nested case-control study in
veterans with diabetes,” Am J Gastroenterol, vol. 5, pp. 1241-8, 2009.
[28] Y. Vinogradova, J. Hiisley, and C. Coupland, “Risk of colorectal cancer in patients prescribed statins, nonsteroidal antiinflammatory
drugs, and cyclooxygenase-2 inhibitors: nested case-control study,” Gastroenterology, vol. 2, pp. 393-402,
2007.
[29] American Heart Association, January 23, 2008.
[30] Ben Kim, “Why Drinking Too Much Water Can Be Harmful To Your Health,” 2013.
[Online] Available: http://drbenkim.com/drink-too-much-water-dangerous.html (13-05-2013)
[31] E. Thorp, T. Iwawaki, and M. Miura, “A reporter for tracking the UPR in vivo reveals patterns of temporal and cellular
stress during atherosclerotic progression,” The Journal of Lipid Research, vol. 52, pp. 1033-1038, 2011.
[32] Bo Feng, and Pin Mei Yao, “The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages,”
Nature Cell Biology, vol. 5, pp. 781–792, 2003.
[33] WHO Regional Office for Europe, World Health Organization, “The prevention and control of major cardiovascular
diseases,” 1st congress called Conference on the Prevention and Control of Cardiovascular Diseases, Euro 8214, Brussels,
18-23 June, 1973.
[34] C. Froelicher, and E. Sivarajan, “The Global Burden of Cardiovascular DiseaseDeaton,” Journal of Cardiovascular Nursing,
vol. 4, S5-S14, 2011.
[35] World Health Organization, Cardiovascular Diseases (CVDs), Fact sheet N°317, March 2013.
[Online] Available: http://www.who.int/mediacentre/factsheets/fs317/en/index.html (26-03-2013)
[36] WHO, World health report 2013: Research for universal health coverage, 2013.
[Online] Available: http://www.who.int/whr/2002/chapter4/en/index4.html (26-03-2013)
[37] H. Kesteloot, S. Sans, and D. Kromhout, “Dynamics of cardiovascular and all-cause mortality in Western and Eastern
Europe between 1970 and 2000,” Eur Heart J, vol. 27, pp. 107-13, 2006.
[38] Linus Pauling Institute Micronutrient Information Center, “Coenzyme Q10,” 2013.
[Online] Available : http://lpi.oregonstate.edu/infocenter/othernuts/coq10/index.html (2013)
[39] D. Preiss, SR. Seshasai, and P. Welsh, “Risk of incident diabetes with intensive-dose compared with moderate-dose
statin therapy: a meta-analysis,” JAMA, vol. 305, no. 24, pp. 2556-64, 2011.
[40] T.B. Horwich, M.A. Hamilton, and W.R. Maclellan, “Low serum total cholesterol is associated with marked increase in
mortality in advanced heart failure,” J Card Fail, vol. 4, pp. 216-24, 2002.
[41] Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D, “Hyperlipidemia and Coronary Disease Correction of
the Increased Thrombogenic Potential With Cholesterol Reduction,” Circulation, vol. 92, no. 11, pp. 3172-7, 1995.
[42] Keys A. Seven Countries. A Multivariate Analysis of Death and Coronary Heart Disease. Cambridge/London: Harvard
University Press; 1980.
Insights on cholesterol nutrition: shift to a new paradigm for better cardiovascular health
ISSN : 2028-9324 Vol. 4 No. 3, Nov. 2013 522
[43] W.P. Castelli, R.J. Garrison, and PWF. Wilson, “Incidence of coronary heart disease and lipoprotein cholesterol levels:
the Framingham Study,” JAMA, vol. 256, pp. 2835-2838, 1986.
[44] National Cholesterol Education Program Adult Treatment Panel II, “Second Report of the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II),” Circulation, vol. 89, pp. 1339-
1446, 1994.
[45] J. Stamler and D. Wentworth, “Is the relationship between serum cholesterol and risk of premature death from
coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor
Intervention Trial (MRFIT),” JAMA, vol. 256, pp. 2823-2828, 1986.
[46] M.R. Law, N.J. Wald, and S.G. Thompson, “By how much and how quickly does reduction in serum cholesterol
concentration lower risk of ischemic heart disease?” Br Med J., vol. 308, pp. 367-373, 1994.
[47] G. Brown, JJ. Albers, and LD. Fisher, “Regression of coronary artery disease as a result of intensive lipid-lowering therapy
in men with high levels of apolipoprotein B,” N Engl J Med., vol. 323, pp. 1289-1298, 1990.
[48] J.E. Rossouw, B. Lewis, and B.M. Rifkind, “The value of lowering cholesterol after myocardial infarction,” N Engl J Med.,
vol. 323, pp. 1112-1119, 1990.
[49] G.F. Watts, B. Lewis, and J.N.H. Brunt, “Effects on coronary artery disease of lipid-lowering diet, or diet plus
cholestyramine, in the St Thomas’ Atherosclerosis Regression Study (STARS),” Lancet, vol. 339, pp. 563-569, 1992.
[50] J.F. Brensike, R.I. Levy, and S.F. Kelsey, “Effects of therapy and cholestyramine on progression of coronary
arteriosclerosis,” Results of the NHLBI Type II Coronary Intervention Study Circulation, vol. 69, pp. 313-324, 1984.
[51] R. Doll and A.B. Hill, “Mortality of British doctors in relation to smoking: observations on coronary thrombosis,” Natl
Cancer Inst Monogr, vol. 19, pp. 205–68, 1996.
[52] Heart and stroke facts, Dallas, TX, American Heart Association, 2001.
[53] A. Schmermund, S. Achenbach, and T. Budde, “Effect of intensive versus standard lipid-lowering treatment with
atorvastatin on the progression of calcified coronary atherosclerosis over 12 months, a multicenter, randomized,
double-blind trial,” Circulation, vol. 3, pp. 427-37, 2006.
[54] N. Afsarmanesh, T.B. Horwich, and G.C. Fonarow, “Total cholesterol levels and mortality risk in nonischemic systolic
heart failure,” Am Heart J, vol. 6, pp. 1077-83, 2006.
[55] S.M. Rubin, S. Sidney, and D.M. Black, “High blood cholesterol in elderly men and the excess risk for coronary heart
disease,” Ann Intern Med, vol. 12, pp. 916-20, 1990.
[56] U. Ravnskov, “High cholesterol may protect against infections and atherosclerosis,” QJM: Monthly Journal of the
Association of Physicians, vol. 12, pp. 927-34, 2003.
[57] Flegel WA, Wölpl A, Männel DN, Northoff H, “Inhibition of endotoxin-induced activation of human monocytes by human
lipoproteins,” Infect Immun 57, 2237-2245, 1989.
[58] R.H. Fiser, J.C. Denniston, and R.B. Rindsig, “Effects of acute infection on cholesterolgenesis in the Rhesus monkey,”
Proc Soc Exp Biol Med, vol. 138, pp. 605–9, 1971.
[59] J.M. Cavaillon, C. Fitting, and S.J. Kirsch, “Cytokine response by monocytes and macrophages to free and lipoproteinbound
lipopolysaccharide,” Infect Immun, vol. 58, pp. 2375–82, 1990.
[60] I. Hardardottir, C. Grunfeld, and KR. Feingold, “Effects of endotoxin on lipid metabolism,” Biochem Soc Trans, vol. 23,
pp. 1013–18, 1995.
[61] C. Grunfeld and KR. Feingold, “Regulation of lipid metabolism by cytokines during host defense,” Nutrition, Vol. 12, S24–
6, 1996.
[62] G. Liuzzo, “Atherosclerosis: an inflammatory disease,” Rays, vol. 26, no. 4, pp. 221-30, 2001.
[63] J. Abramson, and J.M. Wright, “Are lipid-lowering guidelines evidence-based?” Lancet, vol. 369, pp. 168-9, 2007.
[64] R.A. Davidson, “Statins reduce mortality and cardiovascular events in adults at risk for cardiovascular disease,” Ann
Intern Med, vol. 151, JC4-14, 2009.
[65] Ingelsson E, Schaefer EJ, Contois JH, McNamara JR, Sullivan L, Keyes MJ, Pencina MJ, Schoonmaker C, Wilson PW,
D'Agostino RB, Vasan RS, “Clinical utility of different lipid measures for prediction of coronary heart disease in men and
women,” JAMA, vol. 298, no. 7, pp. 776-785, 2007.
[66] A. Wazana, “Is a gift ever just a gift?,” Journal of the American Medical Association, vol. 283, pp. 373-380, 2000.
[67] TheHuffingtonPost, Auction 2012: How Drug Companies Game Washington, 2012.
[Online] Available: http://www.huffingtonpost.com/2012/02/01/auction-2012-drug-companies-lob...
(21-02-2013)
[69] C. Weinstock, H. Ullrich, and R. Hohe, “Low density lipoproteins inhibit endotoxin activation of monocytes,” Arterioscler
Thromb Vasc Biol, vol. 12, pp. 341–7, 1992.
[71] KR. Feingold, and C. Grunfeld, “Role of cytokines in inducing hyperlipidemia,” Diabetes, vol. 32, pp. 97–101, 1992.
[72] I. Hardardottir, C. Grunfeld, and KR. Feingold, “Effects of endotoxin on lipid metabolism,” Biochem Soc Trans, vol. 23,
pp. 1013–18, 1995.
Ghose Bishwajit, Marce - Amara Kpoghomou, Hasanbek Shamsitdinov, Arun Kumar Mondal, and Sudeb Sarker
ISSN : 2028-9324 Vol. 4 No. 3, Nov. 2013 523
[73] C. Grunfeld, and KR. Feingold, “Regulation of lipid metabolism by cytokines during host defense,” Nutrition, vol. 12,
S24–6, 1996.
[74] G.K. Hansson, “Mechanisms of disease: inflammation, atherosclerosis, and coronary artery disease,” New England
Journal of Medicine, vol. 16, pp. 1685–1695, 2005.
[75] G.K. Hansson and P. Libby, “The immune response in atherosclerosis: a double-edged sword,” Nature Reviews
Immunology, vol. 7, pp. 508–519, 2006.
[76] R. Ross, “The pathogenesis of atherosclerosis—an update,” N Engl J Med, vol. 314, pp. 488–500, 1986.
[77] U. Ravnskov, “High cholesterol may protect against infections and atherosclerosis,” QJM, vol. 12, pp. 927-934, 2003.
[78] C. Iribarren, “Serum total cholesterol and risk of hospitalization, and death from respiratory disease,” International
Journal of Epidemiology, vol. 26, pp. 1191-1202, 1992.
[79] M. Rauchhaus, “Plasma cytokine parameters and mortality in patients with heart failure,” Circulation, vol. 102, pp.
3060-3067, 2000.
[80] U. Ravenskov, “The Benefits of High Cholesterol,” Well Being Journal, vol. 43, 2004.
[81] GK. Hansson and A. Hermansson, “The immune system in atherosclerosis,” Nature Immunology, vol. 12, pp. 3, 2011.
[82] A.M. Lundberg and G.K. Hansson, “Innate immune signals in atherosclerosis,” Clin Immunol., vol. 134, pp. 5–24, 2010.
[83] J.P. Couerbe, “Du Cerveau considéré sous le point du vue chimique et physiologique,” Annales de Chimie et de
Physique, vol. 56, pp. 160–193, 1834.
[84] G. Tint, A. Batta, and S. Shefer, “The Smith-Lemli-Opitz syndrome: A potentially fatal birth defect caused by a block in
the last enzymatic step in cholesterol biosynthesis,” Cholesterol, New York: Plenum Press, 1998.
[85] P.E. Jira, H.R. Waterham, and R.J. Wanders, “Smith-Lemli-Opitz syndrome and the DHCR7 gene,” Ann Hum Genet., Vol.
67, pp. 269–280, 2003.
[86] G. Snipes and U. Suter, Cholesterol and Myelin, In: Bittman R, ed. Cholesterol. New York: Plenum Press, 1998.
[87] JM. Dietschy, and SD. Turley, “Cholesterol metabolism in the brain,” Curr Opin Lipidol, vol. 12, pp. 105–112, 2001.
[88] A. Chobanian and W. Hollander, “Body cholesterol metabolism in man. I The equilibration of serum and tissue
cholesterol,” J Clin Invest., Vol. 41, pp. 1732–1733, 1962.
[89] Y. Lange, M. Rigney, and T.L. Steck, “Regulation of endoplasmic reticulum cholesterol by plasma membrane
cholesterol,” J Lipid Res, vol. 40, pp. 2264-2270, 1990.
[90] KT. Jones, J. Zhen, and ME. Reith, “Importance of cholesterol in dopamine transporter function,” J Neurochem, vol. 123,
no. 5, pp. 700-15, 2012.
DOI: 10.1111/jnc.12007
[91] M. Martin, C.G. Dotti, and M.D. Ledesma, “Brain cholesterol in normal and pathological aging,” Biochimica et Biophysica
Acta, vol. 8, pp. 934–944, 2010.
[92] M. Saito, E.P. Benson, and M. Saito, “Metabolism of cholesterol and triacylglycerol in cultured chick neuronal cells, glial
cells, and fibroblasts: accumulation of esterified cholesterol in serum-free culture,” Journal of Neuroscience Research,
vol. 2, pp. 319–325, 1987.
[93] S. Suzuki, K. Kiyosue, and S. Hazama, “Brain-derived neurotrophic factor regulates cholesterol metabolism for synapse
development,” Journal of Neuroscience, vol. 24, pp. 6417–6427, 2007.
[94] A. Seneff, “Nutrition and Alzheimer’s disease: The detrimental role of a high carbohydrate diet,” Eur J Int Med, vol. 22,
pp. 134-140, 2011.